OBI Pharma announces acquisition of cancer drug candidate from Threshold Pharmaceuticals

Taipei, Taiwan-headquartered OBI Pharma, Inc., (TPex: 4174), announced last week that an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) had been made to acquire TH-3424, a first-in-class novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).

Read more

High barrier-to-entry API, finished injectables to drive growth in 2017: ScinoPharm CEO

Tainan-headquartered ScinoPharm Taiwan (1789, TaiEx), the country’s leading API manufacturer, will continue its strategy of producing high barrier-to-entry API while vertically expanding its offering to encompass the manufacturing of finished injectable products, reported Chen Yung-fa, ScinoPharm’s President & CEO in a recent interview with PharmaBoardroom.

Read more

Pitfalls of technology licensing, urgent need for training among issues covered at panel discussion on Taiwan’s biologics business environment

To take advantage of its strong science base and a growing number of small innovative companies, Taiwan’s burgeoning biopharmaceutical industry will need to start planning now to develop personnel skilled enough in GMP manufacturing and clinical trials to meet the demands and rigors of such a highly technical field.

Read more